{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:38:42Z","timestamp":1761586722918,"version":"build-2065373602"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The German Dementia Registry (DEMREG) is a large-scale national prospective biomarker-based study for cognitive impairment and dementia, providing an integrated clinical research platform for research studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The DEMREG study longitudinally collects demographic, clinical, genetic, biological, and imaging data, along with risk factors and treatment information from real-world settings. Comprehensive clinical assessments are conducted yearly. This extensive resource enables researchers to investigate current diagnostic and treatment practices and explore the complex relationships between risk factors and outcomes. The registry is now active across 22 sites in Germany, all members of the the German Memory Clinic Network (DNG), with more than 500 patients recruited to date, and is expected to include up to 1.000 patients annually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Perspective<\/jats:title>\n                    <jats:p>The DEMREG study represents a large nationally harmonized cohort of detailed real-world clinical and biological data from patients with cognitive impairment and dementia, enabling insights into long-term dynamics and treatment responses. This infrastructure has the potential to foster collaborative research and roll out healthcare innovations across different settings in Germany. In this context, a substudy will soon be conducted to evaluate long-term safety and efficacy measures of the new monoclonal antibodies targeting amyloid plaques in a clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The protocol is registered at German Clinical Trials Register (DRKS00027547), Date of Registration: 01.04.2022.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-025-00433-9","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:32:03Z","timestamp":1761586323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The\u00a0German Dementia Registry (DEMREG): study protocol of a biomarker-based national registry for cognitive impairment and dementia"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-9228","authenticated-orcid":false,"given":"Kathrin","family":"Reetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Sofia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Moschko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"H\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Schuckelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"R\u00f6hrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Wienstr\u00f6er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Fl\u00f6el","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emrah","family":"D\u00fczel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oezguer A.","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The German Dementia Registry (DEMREG) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f6rte","family":"Polivka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Duning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gutschalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Oberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlena","family":"Schnieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Trender-Gerhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Laske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Dahling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Saur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eike","family":"Spruth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Fu\u00dfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzel","family":"Glanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrezia","family":"Hausner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Riemenschneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"H\u00f6ltje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Hellmann-Regen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"433_CR1","unstructured":"DGN, DGPPN. S3-Leitlinie Demenzen. Version 50, 28022025; https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-013https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-0132025. DGN e. V. & DGPPN e. V. (Hrsghttps:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-013, 12. June 2025."},{"key":"433_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). \u201cMini-mental state\u201d A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189\u2013198.","journal-title":"Journal of Psychiatric Research"},{"key":"433_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S., Phillips, N. A., B\u00e9dirian, V., et al. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53, 695\u2013699.","journal-title":"Journal of the American Geriatrics Society"},{"key":"433_CR4","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. (1993). The clinical dementia rating (CDR): Current version and scoring rules. Neurology, 43, 2412\u20132414.","journal-title":"Neurology"},{"key":"433_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer\u2019s disease. American Journal of Psychiatry, 141, 1356\u20131364.","journal-title":"American Journal of Psychiatry"},{"key":"433_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/archneur.1991.00530150046016","volume":"48","author":"K Welsh","year":"1991","unstructured":"Welsh, K., Butters, N., Hughes, J., Mohs, R., & Heyman, A. (1991). Detection of abnormal memory decline in mild cases of Alzheimer\u2019s disease using CERAD neuropsychological measures. Archives Of Neurology, 48, 278\u2013281.","journal-title":"Archives Of Neurology"},{"key":"433_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00002093-199700112-00005","volume":"11","author":"D Galasko","year":"1997","unstructured":"Galasko, D., Bennett, D., Sano, M., et al. (1997). An inventory to assess activities of daily living for clinical trials in alzheimer\u2019s disease. Alzheimer Disease and Associated Disorders, 11, 33\u201339.","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"433_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","volume":"17","author":"JA Yesavage","year":"1983","unstructured":"Yesavage, J. A., Brink, T. L., Rose, T. L., et al. (1983). Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research, 17, 37\u201349.","journal-title":"Journal of Psychiatric Research"},{"key":"433_CR9","volume-title":"Evaluation of the resource utilization and caregiver time in Anti-dementia drug trials\u2014A quantitative battery","author":"A Wimo","year":"1998","unstructured":"Wimo, A., Wetterholm, A., Mastey, V., & Winblad, B. (1998). Evaluation of the resource utilization and caregiver time in Anti-dementia drug trials\u2014A quantitative battery. Wiley\u2019s London."},{"key":"433_CR10","first-page":"649","volume":"20","author":"SH Zarit","year":"1980","unstructured":"Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980). Relatives of the impaired elderly: Correlates of feelings of burden. Gerontology, 20, 649\u2013655.","journal-title":"Gerontology"},{"key":"433_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2012-302562","volume":"83","author":"P Scheltens","year":"2012","unstructured":"Scheltens, P., & van de Pol, L. (2012). Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: Diagnostic value and neuropsychological correlates. Journal of Neurology, Neurosurgery, And Psychiatry, 83, 1038.","journal-title":"Journal of Neurology, Neurosurgery, And Psychiatry"},{"key":"433_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000117417","volume":"37","author":"P Scheltens","year":"1997","unstructured":"Scheltens, P., Pasquier, F., Weerts, J. G. E., Barkhof, F., & Leys, D. (1997). Qualitative assessment of cerebral atrophy on MRI: Inter- and intra-observer reproducibility in dementia and normal aging. European Neurology, 37, 95\u201399.","journal-title":"European Neurology"},{"key":"433_CR13","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"ELGE Koedam","year":"2011","unstructured":"Koedam, E. L. G. E., Lehmann, M., van der Flier, W. M., et al. (2011). Visual assessment of posterior atrophy development of a MRI rating scale. European Radiology, 21, 2618\u20132625.","journal-title":"European Radiology"},{"key":"433_CR14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund, L. O., Barkhof, F., Fazekas, F., et al. (2001). A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke, 32, 1318\u20131322.","journal-title":"Stroke"},{"key":"433_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3233\/JAD-170793","volume":"62","author":"J Vogelgsang","year":"2018","unstructured":"Vogelgsang, J., Wedekind, D., Bouter, C., Klafki, H.-W., & Wiltfang, J. (2018). Reproducibility of Alzheimer\u2019s disease cerebrospinal fluid-biomarker measurements under clinical routine conditions. Journal of Alzheimer\u2019s Disease, 62, 203\u2013212.","journal-title":"Journal of Alzheimer's Disease"},{"key":"433_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3233\/JAD-2010-100207","volume":"21","author":"J Hertze","year":"2010","unstructured":"Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010). Evaluation of CSF biomarkers as predictors of Alzheimer\u2019s disease: A clinical follow-up study of 4.7 years. Journal of Alzheimer\u2019s Disease, 21, 1119\u20131128.","journal-title":"Journal of Alzheimer's Disease"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00433-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:32:04Z","timestamp":1761586324000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00433-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00433-9","relation":{},"ISSN":["2524-3489"],"issn-type":[{"type":"electronic","value":"2524-3489"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is carried out in accordance with the Declaration of Helsinki of the World Medical Association and according to the principles of Good Clinical Practice (GCP) and good scientific practice (GSP). Study participation is voluntary and can be withdrawn at any time. Written informed consent will be obtained prior to participation, if applicable. Patients will be fully informed about aims, procedures, data collection, and the use of collected data in this registry. Refusing participation has no negative consequences for patients. No foreseeable risk results from participating. No compassionate use is carried out. No invasive interventions are conducted. This study is registered at the German Clinical Trials Register (DRKS00027547). Principles of data protection will be upheld. The study has received approval from the local ethics committee (Ethics Board of the Faculty of Medicine at RWTH Aachen University (EK 279\/21)). The results of this study will be disseminated via peer-reviewed journals. Deviations from the protocol (e.g. inclusion, recruitment and procedures) will be discussed. This manuscript has been written according to the SPIRIT guidance\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The contractual partners endeavour to publish the results of their work jointly, and all publications will specify that the results were obtained within the German Dementia Registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KR reports receiving consulting fees from Biogen, Eisai, Lilly and Roche. ASC has received speaker honoraria from Eisai and Lilly and services honoraria from Biogen. AH has received speaker honoraria from Eisai. TO has received speaker honoraria from Lilly, Biogen and Siemens Healthineers. OAO reports receiving consulting fees and speaker honoraria from Biogen, Eisai, Lilly, GE, Synaptikon and Boston Scientific. Outside the submitted work TG reported receiving consulting fees from Acumen, Advantage Ther, Alector, Anavex, Biogen, BMS; Cogthera, Eisai, Eli Lilly, Functional Neuromod., Grifols, Janssen, Neurimmune, Noselab, Novo Nordisk, Roche Diagnostics, and Roche Pharma;\u00a0lecture fees from Anavex, Cogthera, Eisai, Eli Lilly, FEO, Grifols, Pfizer, Roche Pharma, Schwabe, and Synlab;\u00a0and has received grants to his institution from Biogen,Eisai and Eli Lilly.\u00a0VD has received speaker honoraria from Lilly and sponsorship of scientific events by Eisai, Lilly and Novo Nordisk. JL reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Lilly, BIAL, Merck and Roche, consulting fees from Axon Neuroscience, EISAI, Lilly, Roche and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent \u201cOral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies\u201d (PCT\/EP2024\/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent \u201cPharmaceutical Composition and Methods of Use\u201d (EP 22 159 408.8) filed by MODAG GmbH. DS receives lecture fees from Lilly and Eisai. FJ has received personal fees for funding and advisory services from the following companies: AC Immune, Biogen, Eisai, GE Healthcare, Grifols, Janssen, Lilly, Novo Nordisk, and Roche.\u00a0All others report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}